Want to see TSE:ACB full AI Analyst Report?
ACB Stock Chart & Stats
C$5.04
-C$0.40(-5.99%)
At close: 4:00 PM EST
C$5.04
-C$0.40(-5.99%)
Day’s Range― - ―
52-Week RangeC$3.69 - C$9.33
Previous CloseN/A
Volume150.63K
Average Volume (3M)413.57K
Market Cap
C$235.38M
Enterprise ValueC$144.59M
Total Cash (Recent Filing)C$164.69M
Total Debt (Recent Filing)C$23.86M
Price to Earnings (P/E)―
Beta1.70
Next Earnings
Aug 12, 2026EPS Estimate
-0.17Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.14
Shares Outstanding61,942,146
10 Day Avg. Volume305,216
30 Day Avg. Volume413,568
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)0.51
Price to Sales (P/S)0.81
P/FCF Ratio-7.20
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
C$6.13Price Target Upside21.53% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)-0.28
Revenue Forecast (FY)C$289.50M
Bulls Say, Bears Say
Bulls Say
International DiversificationA majority of revenue coming from international markets reduces reliance on the Canadian market and its regulatory cycles. Durable exposure to Europe, Australia and other medical markets supports higher-margin medical sales and provides structural revenue diversification as domestic headwinds occur.
High Adjusted Margins & EBITDAIndustry-leading adjusted gross margins and meaningful EBITDA growth indicate sustainable product mix and operating leverage in medical channels. Strong margin profile provides capacity to fund EU expansion, absorb some pricing pressure, and improves runway for profitable scaling over the medium term.
Improved Liquidity & DeleveragingA large cash balance combined with sharply reduced debt materially increases financial flexibility. This durable balance-sheet strength supports opportunistic M&A, capital spending (EU‑GMP capacity), and buffers near-term revenue resets without immediate refinancing pressure.
Bears Say
Regulatory Pricing Cut In CanadaA material, structural reimbursement cut in Canada directly lowers medical revenue and compresses margins in a core market. Given Canada’s historical importance, this regulatory shift forces a strategic reallocation of resources and creates sustained revenue pressure until international growth offsets the loss.
Weak And Inconsistent Cash GenerationReturn to negative operating cash flow and persistent negative free cash flow undermine internal funding capacity. Over several months this increases dependence on capital markets or asset sales to fund operations and strategic investments, raising execution and liquidity risk during industry volatility.
Revenue Volatility And Return To LossesA recent revenue decline and swing to significant losses signal fragile earnings quality. Persistent volatility limits long-term planning, can erode equity value if sustained, and places pressure on margins and investment prioritization until consistent profitable growth is re-established.
Aurora Cannabis News
ACB FAQ
What was Aurora Cannabis (US)’s price range in the past 12 months?
Aurora Cannabis (US) lowest stock price was C$3.69 and its highest was C$9.33 in the past 12 months.
What is Aurora Cannabis (US)’s market cap?
Aurora Cannabis (US)’s market cap is C$235.38M.
When is Aurora Cannabis (US)’s upcoming earnings report date?
Aurora Cannabis (US)’s upcoming earnings report date is Aug 12, 2026 which is in 27 days.
How were Aurora Cannabis (US)’s earnings last quarter?
Aurora Cannabis (US) released its earnings results on Jun 11, 2026. The company reported -C$0.48 earnings per share for the quarter, missing the consensus estimate of -C$0.058 by -C$0.422.
Is Aurora Cannabis (US) overvalued?
According to Wall Street analysts Aurora Cannabis (US)’s price is currently Undervalued.
Does Aurora Cannabis (US) pay dividends?
Aurora Cannabis (US) does not currently pay dividends.
What is Aurora Cannabis (US)’s EPS estimate?
Aurora Cannabis (US)’s EPS estimate is -0.17.
How many shares outstanding does Aurora Cannabis (US) have?
Aurora Cannabis (US) has 61,942,146 shares outstanding.
What happened to Aurora Cannabis (US)’s price movement after its last earnings report?
Aurora Cannabis (US) reported an EPS of -C$0.48 in its last earnings report, missing expectations of -C$0.058. Following the earnings report the stock price went down -6.754%.
Which hedge fund is a major shareholder of Aurora Cannabis (US)?
Currently, no hedge funds are holding shares in TSE:ACB
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Aurora Cannabis Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
C$6.13 (21.53% Upside)
C$6.13 (21.53% Upside)
Blogger Sentiment
Bullish
TSE:ACB Sentiment 70%
Sector Average 67%
Sector Average 67%
Insider Transactions
Sold Shares
Worth C$66.9K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 27.4%
Last 30 Days ▲ 23.7%
Last 30 Days ▲ 23.7%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-40.75%
12-Months-Change
Fundamentals
Return on Equity
-14.05%
Trailing 12-Months
Asset Growth
-27.30%
Trailing 12-Months
Company Description
Aurora Cannabis (US)
Aurora Cannabis Inc. is a Canada-based firm specializing in the cultivation, processing, and global distribution of cannabis and its various derivative products. The company's operations encompass a broad spectrum of the cannabis industry, from facility engineering and design to genetic research, production, and the development of new products, all supported by extensive wholesale and retail networks. For medical users, Aurora offers diverse strains of dried cannabis, oils, capsules, and topical kits. Additionally, it markets a range of accessories, including vaporizers, consumable parts, herb mills (specifically for CanniMed products), grinders, and lockable vaporizer containers. The company is committed to advancing medical cannabis, with ongoing development across oral, topical, edible, and inhalable product categories. Aurora also provides key services such as patient counseling, design and construction assistance, and comprehensive analytical product testing for cannabis, alongside operating CanvasRX, a network dedicated to cannabis counseling and outreach. Its expansive brand family includes Aurora, Aurora Drift, San Rafael '71, Daily Special, AltaVie, MedReleaf, CanniMed, Whistler, Woodstock, and WMMC. The corporate headquarters are located in Edmonton, Canada.
ACB Stock 12 Month Forecast
Average Price Target
C$6.13
▲(21.53% Upside)